The Q2 results did not throw up any surprises, but the generic erosion was seen as tapering down and the new products rising to the occasion. The oncology drug, Tagrisso, has been showing an excellent trajectory while the other oncology drugs are lending good support. The overhang of genericisation continued to weigh on the legacy drugs but respiratory’s resilience during the quarter was a positive development. The last six months have been mixed for R&D, which otherwise is well sto
05 Sep 2018
Emerging markets shine but R&D progress at a critical stage
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Emerging markets shine but R&D progress at a critical stage
AstraZeneca PLC (AZN:LON) | 11,224 2020.3 0.2% | Mkt Cap: 173,998m
- Published:
05 Sep 2018 -
Author:
Kamla Singh -
Pages:
4
The Q2 results did not throw up any surprises, but the generic erosion was seen as tapering down and the new products rising to the occasion. The oncology drug, Tagrisso, has been showing an excellent trajectory while the other oncology drugs are lending good support. The overhang of genericisation continued to weigh on the legacy drugs but respiratory’s resilience during the quarter was a positive development. The last six months have been mixed for R&D, which otherwise is well sto